John Reed (Endpoints JPM19, Jeff Rumans)
Analysts poured cold water, but FDA gives a fast-pass for Sanofi's new Pompe disease drug
Analysts didn’t love the results from Sanofi’s pivotal Pompe disease study, but the FDA has evidently seen enough promise to give it an expedited …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
